Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
AstraZeneca
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
AstraZeneca
Memorial Sloan Kettering Cancer Center
BioNTech SE
Faeth Therapeutics
GlaxoSmithKline
Fate Therapeutics
Washington University School of Medicine
M.D. Anderson Cancer Center
Yonsei University
Huabo Biopharm Co., Ltd.
Hutchmed
Leiden University Medical Center
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.